Cvs Health vs Elevance Health
CVS and ELV side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVS and ELV compare
Cvs Health is the larger company, worth 1.2 times as much as Elevance Health ($115B against $92.9B).
On earnings, Cvs Health is cheaper: it trades at 10.5× trailing earnings, against 18.3× for Elevance Health.
Cvs Health grew revenue faster over the last twelve months (6.7% versus 3.6% for Elevance Health).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with 2.5% at Elevance Health.
Both pay dividends: Cvs Health yields 2.2% and Elevance Health 1.6%.
Cvs Health scores higher on the StockData Score (19 against 15 for Elevance Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVS | ELV |
|---|---|---|
| Size and price | ||
| Market cap | $115B | $92.9B |
| Share price | $89.79 | $429.90 |
| Change, 1 year | 12.4% | 36.4% |
| Change, 5 years | −3.6% | 3.5% |
| Beta (5Y) | 0.50 | 0.45 |
| Employees | 300K | 97K |
| StockData Score | ||
| Total score | 19 (better) | 15 |
| Valuation score | 6 (better) | 4 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 2 | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 10.5× (better) | 18.3× |
| P/S | 0.3× (better) | 0.5× |
| P/B | 1.4× (better) | 2.1× |
| EV/EBITDA | 8.2× (better) | 12.7× |
| P/FCF | 7.4× (better) | 14.3× |
| PEG | – | 14.54 |
| FCF yield | 13.6% (better) | 7.0% |
| Fair value | $126.85 | $496.28 |
| Margin of safety | 29.2% (better) | 13.4% |
| Growth | ||
| Revenue growth (TTM) | 6.7% (better) | 3.6% |
| Revenue growth, 5Y average | 8.4% | 10.3% (better) |
| Net income growth (TTM) | 2253% (better) | −7.1% |
| EPS growth (TTM) | 2158% (better) | −4.1% |
| EPS growth, 5Y average | −23.9% | 7.0% (better) |
| Profitability | ||
| Gross margin | 44.2% | 89.0% (better) |
| Operating margin | 3.6% (better) | 2.7% |
| Net margin | 2.6% (better) | 2.5% |
| FCF margin | 3.7% (better) | 3.2% |
| Return on equity | 14.4% (better) | 11.6% |
| Return on invested capital | 10.8% | 11.0% (better) |
| Financial health | ||
| Debt / equity | 0.75 | 0.69 (better) |
| Net debt / EBITDA | 2.34 (better) | −0.71 |
| Interest coverage | 4.9× (better) | 3.8× |
| Current ratio | 0.85 | 1.47 (better) |
| Altman Z-score | 2.51 | 3.01 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.2% (better) | 1.6% |
| Payout ratio | 31.0% | 29.2% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 5.9% | – |
| Buyback yield | – | 2.3% |
| Shareholder yield | 2.2% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 89.2% | 94.3% |
| Held by insiders | 0.43% | 0.18% |
| Insider net buying, 12 months | −$322M | −$4.7M (better) |
| Superinvestors holding | 6 | 8 (better) |
| Short interest, % of float | 1.4% | 2.1% |
Go deeper
- CVS stock overview
- CVS income statement
- CVS valuation and score
- ELV stock overview
- ELV income statement
- ELV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.